All In Biotech

Free tool

FAERS Monitor: Esmolol Hydrochloride Double Strength In Plastic Container

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205703 or its brand name (Esmolol Hydrochloride Double Strength In Plastic Container, Esmolol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

115

Serious

104

90% of reports

Hospitalization

43

Death reported

17

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective22
  • product use issue15
  • product use in unapproved indication12
  • cardiac arrest7
  • condition aggravated6
  • drug ineffective for unapproved indication6
  • hepatotoxicity6
  • hyperbilirubinaemia6
  • hypotension6
  • cardiogenic shock5
  • hepatomegaly5
  • hypertension5
  • overdose5
  • renal failure5
  • respiratory arrest5

Reports by year received

View as table
YearReports
20091
20123
20132
20142
20152
20161
20174
20187
201912
20205
202113
20229
202318
20247
202522
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,044 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperbilirubinaemiaSignal6106.048.6523
hepatomegalySignal593.139.5368
cardiogenic shockSignal563.727.0249
hepatotoxicitySignal649.322.6238
respiratory arrestSignal533.214.1126
drug ineffective for unapproved indicationSignal620.09.290
cardiac arrestSignal715.57.681
product use issueSignal1514.69.1178
product use in unapproved indicationSignal128.95.277
renal failureSignal56.92.920
hypotensionSignal65.52.518
hypertensionSignal54.31.810
overdoseSignal54.21.89
condition aggravatedSignal63.61.79
drug ineffectiveSignal223.12.130

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.